文献速递生殖医学产科

冻胚移植后早期妊娠中PAPP-A与IGF-1浓度:一项随机对照试验的二次分析

Early pregnancy concentrations of pregnancy-associated plasma protein-A (PAPP-A) and insulin-like growth factor-1 (IGF-1) following frozen embryo transfer: secondary analyses from a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2026-01-01

该研究为一项随机对照试验的二次分析,纳入116例持续妊娠妇女,比较冻胚移植方案对早期妊娠PAPP-A和IGF-1浓度的影响。结果显示,排卵妇女中程序周期(PC)组的PAPP-A和IGF-1浓度显著低于改良自然周期(mNC)组,无排卵妇女中PC组的PAPP-A也低于促性腺激素刺激周期(gSC)组。

要点

  • PC-FET与早期妊娠PAPP-A和IGF-1浓度降低相关。
  • 排卵妇女中PC组PAPP-A在内膜准备、移植日及GA 4+2均低于mNC组。
  • 无排卵妇女中PC组内膜准备期PAPP-A低于gSC组。

核心结论

  • 与mNC-FET和gSC-FET相比,PC-FET后早期妊娠IGF-1浓度更低,PAPP-A呈时间依赖性降低。

研究设计与样本

  • 一项随机对照试验的二次分析,在丹麦哥本哈根大学医院-Herlev进行,纳入持续妊娠妇女116例(排卵mNC组43例、排卵PC组42例、无排卵gSC组16例、无排卵PC组15例),另对193例有生物样本的排卵妇女进行IGF-1分析。

主要发现

  • 排卵妇女中,PC组PAPP-A在内膜准备期(7.4 vs 8.7 mU/l;校正P=0.02)、移植日(6.7 vs 8.8 mU/l;校正P<0.001)和GA 4+2(7.2 vs 8.5 mU/l;校正P=0.03)均显著低于mNC组。
  • 无排卵妇女中,PC组内膜准备期PAPP-A显著低于gSC组(5.8 vs 9.1 mU/l;校正P=0.008)。
  • PC组从治疗开始至GA 8+0的IGF-1浓度显著低于mNC组和gSC组。

临床怎么用

  • PC-FET后早期胎盘功能标志物降低,可能部分解释其不良产科风险,提示需关注PC-FET妊娠的胎盘相关并发症。

局限性

  • 作为二次分析,未进行正式功效计算,统计功效可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are maternal concentrations of pregnancy-associated plasma protein-A (PAPP-A) and insulin-like growth factor-1 (IGF-1) influenced by the frozen embryo transfer (FET) protocol in early pregnancy? SUMMARY ANSWER: Maternal concentrations of PAPP-A and IGF-1 were significantly lower in programmed cycle (PC) FET compared to modified natural cycle (mNC) FET among ovulatory women and compared to gonadotrophin-stimulated cycle (gSC) FET in anovulatory women. WHAT IS KNOWN ALREADY: PC-FET has been associated with increased risks of preeclampsia and other placenta-related complications, pointing to altered placental development. PAPP-A and IGF-1 are biochemical markers of early placental function, and reduced levels have been linked to preeclampsia and other adverse outcomes. These markers may therefore provide insight into the pathways underlying the distinct risk profile of PC-FET. STUDY DESIGN, SIZE, DURATION: This is a secondary analysis from a randomized controlled trial investigating estradiol and progesterone concentrations in FET treatments. The trial was conducted at Copenhagen University Hospital-Herlev, Denmark, from April 2021 to December 2024. Biochemical analyses for PAPP-A and IGF-1 were performed on stored biobank samples from the trial. The main analyses included women with ongoing pregnancies (n = 116), while additional analyses of IGF-1 were conducted in all ovulatory women with available biobank samples (n = 193). PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible participants were women aged 18-40 years with BMI ≤35 kg/m2 undergoing frozen-thawed autologous blastocyst transfer. Ovulatory women were randomized to mNC or PC, and anovulatory women to gSC or PC. Samples were collected at the following 7 timepoints throughout treatment: on the 2nd or 3rd day of menstrual bleeding, on the day of trigger/endometrial thickness ≥7 mm, on the day of embryo transfer and by gestational ages (GA) 4 + 2, 6 + 0, 8 + 0, and 9 + 6. Data on placental weight were collected at delivery. MAIN RESULTS AND THE ROLE OF CHANCE: The present analyses included women with ongoing pregnancies from the parent trial: 43 in the ovulatory mNC group, 42 in the ovulatory PC group, 16 in the anovulatory gSC group, and 15 in the anovulatory PC group. PC had substantially lower IGF-1 concentrations from treatment initiation through GA 8 + 0 compared to both mNC and gSC. Ovulatory women treated with PC showed significantly lower PAPP-A concentrations during endometrial preparation (7.4 vs 8.7 mU/l; adjusted P = 0.02), at embryo transfer (6.7 vs 8.8 mU/l; adjusted P < 0.001), and GA 4 + 2 (7.2 vs 8.5 mU/l; adjusted P = 0.03) than women treated with mNC. Among anovulatory women, PAPP-A concentrations were also reduced during endometrial preparation (5.8 vs 9.1 mU/l; adjusted P = 0.008) in PC compared to gSC. LIMITATIONS, REASONS FOR CAUTION: As this was a secondary analysis, no formal power calculation was made, and statistical power may therefore be limited. WIDER IMPLICATIONS OF THE FINDINGS: We provide evidence that PC-FET was followed by lower IGF-1 concentrations in early pregnancy and by time-dependent reductions in PAPP-A compared to mNC-FET and gSC-FET. These findings suggest alterations in early placental biology that may contribute to the adverse obstetric risk profile associated with PC-FET. Future studies should clarify whether these changes are related to the use of oral estradiol and whether alternative administration routes could modify this risk. STUDY FUNDING/COMPETING INTEREST(S): The trial was funded by Gedeon Richter Nordics AB, including analysis of biobank samples (grant numbers DK-2019-04, DK-2022-03, DK-2023-08, DK-2023-06, DK-2024-08). The trial also received one grant from the Gangsted-Rasmussen Foundation (grant number A39784) and a grant was obtained from the local research board at Copenhagen University Hospital-Herlev. The study was designed and planned independently, with no involvement from the funders in data analysis or interpretation of the results. N.F.M. has received funding for congress attendance from Gedeon Richter Nordics AB and Merck A/S, unrelated to the present work. B.N. has received grants to the institution from Merck A/S, Gedeon Richter Nordics AB, and Ferring Pharmaceuticals A/S, along with personal fees from Ferring Pharmaceuticals A/S, travel support from Gedeon Richter Nordics AB, and has participated in a data safety monitoring or advisory board for Ferring Pharmaceuticals A/S, outside of this research. M.K. has received funding from Rigshospitalets Research Board outside of this research. L.R. has received a research grant from the Novo Nordisk Foundation outside of this research. P.F.S. has received grants from Merck A/S, Gedeon Richter Nordics AB, and Ferring Pharmaceuticals A/S, travel support from Ferring Pharmaceuticals A/S, and personal fees from Novo Nordisk for webinars, outside of this study. TRIAL REGISTRATION NUMBER: 2020-001218-39 in EudraCT.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Mørch NF, Nøhr B, Kirk M, et al. Early pregnancy concentrations of pregnancy-associated plasma protein-A (PAPP-A) and insulin-like growth factor-1 (IGF-1) following frozen embryo transfer: secondary analyses from a randomized controlled trial. Hum Reprod. 2026. PMID: 41875321. doi:10.1093/humrep/deag044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。